Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Launched by MARIO CASTRO, MD, MPH · Nov 5, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to see how well lungs are working using a special type of MRI with a gas called hyperpolarized (HP) 129Xe. The goal is to find out if this imaging technique can help doctors better understand lung function, especially in people with conditions like asthma, COPD, cystic fibrosis, and other lung diseases. The study is currently recruiting participants, which includes both healthy volunteers and those diagnosed with lung diseases.
To be eligible for this trial, healthy volunteers must not have any lung conditions and should be able to read and understand English or Spanish. Those with lung diseases need to have a diagnosis from a doctor and should not have experienced a serious worsening of their lung function in the past month. Participants can expect to undergo MRI scans where they will need to hold their breath for about 15-16 seconds. It's important to know that certain factors, such as being pregnant or having specific health issues, may prevent someone from participating in the study. This research could lead to better ways to assess and treat lung conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Healthy Volunteers:
- • Subject has no diagnosed pulmonary conditions
- • Ability to read and understand English or Spanish
- Subjects with Lung Disease:
- • Subject has a diagnosis of pulmonary dysfunction made by a physician
- • No acute worsening of pulmonary function in the past 30 days
- • Ability to read and understand English or Spanish
- Exclusion Criteria:
- • MRI is contraindicated based on responses to MRI screening questionnaire
- • Subject is pregnant or lactating
- • Subject does not fit into 129Xe vest coil used for MRI
- • Subject cannot hold his/her breath for 15-16 seconds
- • Subject deemed unlikely to be able to comply with instructions during imaging
- • Oxygen saturation \<88% on room air or with supplemental oxygen
- • Cognitive deficits that preclude ability to provide consent
- • Institutionalization
About Mario Castro, Md, Mph
Dr. Mario Castro, MD, MPH, is a distinguished clinical trial sponsor with extensive expertise in respiratory medicine and public health. With a robust background in conducting innovative research, Dr. Castro is dedicated to advancing medical knowledge and improving patient outcomes through rigorous clinical investigations. His commitment to ethical standards and patient safety, combined with his leadership in multidisciplinary teams, ensures the successful execution of clinical trials that address critical health challenges. Dr. Castro's contributions to the field are marked by his passion for translating research findings into practical applications that enhance healthcare delivery and efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
Patients applied
Trial Officials
Peter Niedbalski, PHD
Principal Investigator
University of Kansas Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials